Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

MLA

Peter Nash, et al. “Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.” Rheumatology and Therapy, vol. 7, no. 3, June 2020, pp. 553–80. EBSCOhost, https://doi.org/10.1007/s40744-020-00209-4.

APA

Peter Nash, Laura C. Coates, Alan J. Kivitz, Philip J. Mease, Dafna D. Gladman, José A. Covarrubias-Cobos, Oliver FitzGerald, Dona Fleishaker, Cunshan Wang, Joseph Wu, Ming-Ann Hsu, Sujatha Menon, Lara Fallon, Ana Belén Romero, & Keith S. Kanik. (2020). Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. Rheumatology and Therapy, 7(3), 553–580. https://doi.org/10.1007/s40744-020-00209-4

Chicago

Peter Nash, Laura C. Coates, Alan J. Kivitz, Philip J. Mease, Dafna D. Gladman, José A. Covarrubias-Cobos, Oliver FitzGerald, et al. 2020. “Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.” Rheumatology and Therapy 7 (3): 553–80. doi:10.1007/s40744-020-00209-4.